posted on 2019-06-03, 13:31authored byJE Emmens, JM Ter Maaten, K Damman, DJ van Veldhuisen, RA de Boer, J Struck, A Bergmann, IE Sama, KW Streng, SD Anker, K Dickstein, CC Lang, M Metra, NJ Samani, LL Ng, AA Voors
BACKGROUND: PENK (proenkephalin) is a stable surrogate for enkephalins, endogenous opioid peptides, which exert cardiodepressive effects and improve renal function. PENK has been associated with heart failure (HF) severity and renal dysfunction. We therefore hypothesized that PENK could be associated with deterioration of kidney function and could have a role as a novel renal marker in HF. METHODS AND RESULTS: In 2180 patients with HF of a large multicenter cohort (BIOSTAT-CHF [A Systems Biology Study to Tailored Treatment in Chronic Heart Failure]), the relationship between PENK and clinical variables, plasma and urinary biomarkers, and clinical end points was established. Data were validated in a separate cohort of 1703 patients with HF. PENK was elevated (>80 pmol/L, 99th percentile) in 1245 (57%) patients. Higher PENK was associated with more advanced HF and glomerular and tubular dysfunction. The strongest independent predictor of PENK was estimated glomerular filtration rate. Others were plasma NGAL (neutrophil gelatinase-associated lipocalin) and NT-proBNP (N-terminal pro-B-type natriuretic peptide; all P<0.001). Using correlation heatmaps and hierarchical cluster analyses, PENK clustered with estimated glomerular filtration rate, creatinine, NGAL, galectin-3, and urea. Higher PENK was independently associated with increased risk of deterioration of kidney function between baseline and 9 months (odds ratio, 1.29 [1.02-1.65] per PENK doubling; P=0.038; defined as >25% decrease in estimated glomerular filtration rate) and mortality (hazard ratio, 1.23 [1.07-1.43] per doubling; P=0.004). Analyses in the validation cohort yielded comparable findings. CONCLUSIONS: Higher PENK levels are associated with more severe HF, with glomerular and tubular renal dysfunction, with incidence of a deterioration of kidney function, and with mortality. These findings suggest that the opioid system might be involved in deteriorating kidney function in HF.
Funding
BIOSTAT-CHF (A Systems Biology Study to Tailored Treatment in Chronic Heart Failure) was funded by the European Commission (FP7-242209-BIOSTAT-CHF and EudraCT 2010-020808-29) and is encompassed in the multidisciplinary scientific consortium RECONNECT (Renal Connection to Microvascular Disease and Heart Failure With Preserved Ejection Fraction).
History
Citation
Circulation: Heart Failure, 2019, 12 (5), e005544
Author affiliation
/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Department of Cardiovascular Sciences
Version
AM (Accepted Manuscript)
Published in
Circulation: Heart Failure
Publisher
American Heart Association, Lippincott, Williams & Wilkins
The file associated with this record is under embargo until 6 months after publication, in accordance with the publisher's self-archiving policy. The full text may be available through the publisher links provided above.;The Data Supplement is available at https://www.ahajournals.org/doi/suppl/10.1161/CIRCHEARTFAILURE.118.005544.